董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Atul Raut | 男 | Director | 53 | 未披露 | 未持股 | 2026-04-21 |
| Susan Benton | 女 | Independent Director | 61 | 未披露 | 12.70 | 2026-04-21 |
| Daphne Haim Langford | 女 | Chairperson of the Board and Chief Executive Officer and Director | 52 | 未披露 | 706.84 | 2026-04-21 |
| Sascha Bucher | 男 | Independent Director | 56 | 未披露 | 12.70 | 2026-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arie Ganot | 男 | Chief Financial Officer | 64 | 未披露 | 未持股 | 2026-04-21 |
| Daphne Haim Langford | 女 | Chairperson of the Board and Chief Executive Officer and Director | 52 | 未披露 | 706.84 | 2026-04-21 |
| Zohar Milman | 女 | Chief Operating Officer | 40 | 未披露 | 57.06 | 2026-04-21 |
| Ron Neumann | 男 | Chief Medical Officer | 71 | 未披露 | 28.77 | 2026-04-21 |
董事简历
中英对照 | 中文 | 英文- Atul Raut
-
Atul Raut担任Tarsier Pharma Ltd.董事会成员，自2019年起担任该职位。Raut博士目前还担任Sun Pharmaceuticals Industries Limited全球业务发展副总裁，该公司是印度最大的制药公司，专注于制造、开发和营销范围广泛的品牌和仿制药配方以及活性制药成分，他于2010年加入该公司。劳特博士负责监督新型特种品牌产品的全球业务发展活动，包括许可、外包许可、并购、合资企业、股权投资以及对风险资本的投资。在加入Sun Pharmaceuticals之前，Raut博士曾在美国爱尔康制药公司担任临床研发经理。Raut博士拥有印度那格浦尔政府医学院的医学博士学位和北德克萨斯大学健康科学中心的药理学和神经科学博士学位。
Atul Raut serves as a member of Tarsier Pharma Ltd.'s board of directors, a position he has held since 2019. Dr. Raut also currently serves as Vice President, Global Business Development at Sun Pharmaceuticals Industries Limited, the largest Indian pharmaceutical company that focuses on manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients, which he joined in 2010. In his role, Dr. Raut oversees global business development activities for novel specialty branded products, including in licensing, out licensing, M&A, Joint Ventures, equity investments as well as investments in venture capitals. Prior to Sun Pharmaceuticals, Dr. Raut served as a Manager in Clinical Research and Development at Alcon Pharmaceuticals in the United States. Dr. Raut holds an M.D. from Government Medical College in Nagpur, India and a Ph.D. in Pharmacology and Neuroscience from the University of North Texas Health Science Center. - Atul Raut担任Tarsier Pharma Ltd.董事会成员，自2019年起担任该职位。Raut博士目前还担任Sun Pharmaceuticals Industries Limited全球业务发展副总裁，该公司是印度最大的制药公司，专注于制造、开发和营销范围广泛的品牌和仿制药配方以及活性制药成分，他于2010年加入该公司。劳特博士负责监督新型特种品牌产品的全球业务发展活动，包括许可、外包许可、并购、合资企业、股权投资以及对风险资本的投资。在加入Sun Pharmaceuticals之前，Raut博士曾在美国爱尔康制药公司担任临床研发经理。Raut博士拥有印度那格浦尔政府医学院的医学博士学位和北德克萨斯大学健康科学中心的药理学和神经科学博士学位。
- Atul Raut serves as a member of Tarsier Pharma Ltd.'s board of directors, a position he has held since 2019. Dr. Raut also currently serves as Vice President, Global Business Development at Sun Pharmaceuticals Industries Limited, the largest Indian pharmaceutical company that focuses on manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients, which he joined in 2010. In his role, Dr. Raut oversees global business development activities for novel specialty branded products, including in licensing, out licensing, M&A, Joint Ventures, equity investments as well as investments in venture capitals. Prior to Sun Pharmaceuticals, Dr. Raut served as a Manager in Clinical Research and Development at Alcon Pharmaceuticals in the United States. Dr. Raut holds an M.D. from Government Medical College in Nagpur, India and a Ph.D. in Pharmacology and Neuroscience from the University of North Texas Health Science Center.
- Susan Benton
-
苏珊·本顿担任Tarsier Pharma Ltd.董事会成员，自2019年3月起担任该职位。本顿女士目前还担任Opus Genetics，Inc.（纳斯达克：IRD）的董事会成员，该公司专注于开发和推进治疗方法，以解决导致视力丧失的基因突变问题，她自2020年以来一直担任该职位。此前，自2022年2024年起，Benson女士担任眼科临床阶段生物技术公司Ripple Therapeutics的董事会成员。自2019年2024年起，本顿女士担任Thea Pharma Inc.的总裁，该公司是一家专门从事眼部护理产品商业化的公司。Benson女士还于2015年至2019年担任Shire plc的全球产品战略和眼科新产品主管，该公司于2019年被Takeda Pharmaceutical Company Limited（NYSE：TAK）收购。在加入Shire之前，2011年至2013年，Benton女士在眼健康公司Bausch + Lomb Corporation（纽约证券交易所代码：BLCO）担任全球业务发展执行董事。Benton co女士创立了Sirion Therapeutics，Inc.并担任其首席商务官，该公司是一家生物制药公司，开发了Durezol（一种用于NIU的类固醇）和Zirgan，后来分别于2010年被爱尔康和Bausch + Lomb收购。此外，Benton女士还在临床开发、战略营销以及商业和商业运营领域担任众多眼科初创公司的战略顾问。本顿女士拥有南弗洛里亚大学MBA学位和穆伦贝格学院生物学学士学位。
Susan Benton serves as a member of Tarsier Pharma Ltd.'s board of directors, a position she has held since March 2019. Ms. Benton also currently serves on the board of Opus Genetics, Inc. (Nasdaq: IRD), a company focused on developing and advancing treatments to address mutations in genes that cause loss of vision, a position she has held since 2020. Previously, from 2022 2024, Ms. Benson served as a member of the board of directors of Ripple Therapeutics, an ophthalmic clinical stage biotech company. From 2019 2024, Ms. Benton was the President of Thea Pharma Inc., a company specializing in the commercialization of eye care products. Ms. Benson also served as the Head of Global Product Strategy and New and New Ophthalmic Products at Shire plc from 2015 2019, a company that was acquired by Takeda Pharmaceutical Company Limited (NYSE: TAK) in 2019. Prior to joining Shire, from 2011 2013, Ms. Benton served as the Executive Director, Global Business Development at Bausch + Lomb Corporation (NYSE: BLCO), an eye health company. Ms. Benton co founded and served as the Chief Commercial Officer for Sirion Therapeutics, Inc., a biopharmaceutical company that developed Durezol (a steroid for NIU) and Zirgan that were later acquired in 2010 by Alcon and Bausch + Lomb, respectively. Additionally, Ms. Benton has served as a strategic consultant for numerous ophthalmic start up companies in the areas of clinical development, strategic marketing, and commercial and business operations. Ms. Benton holds an MBA from the University of South Floria and a B.S. in Biology from Muhlenberg College. - 苏珊·本顿担任Tarsier Pharma Ltd.董事会成员，自2019年3月起担任该职位。本顿女士目前还担任Opus Genetics，Inc.（纳斯达克：IRD）的董事会成员，该公司专注于开发和推进治疗方法，以解决导致视力丧失的基因突变问题，她自2020年以来一直担任该职位。此前，自2022年2024年起，Benson女士担任眼科临床阶段生物技术公司Ripple Therapeutics的董事会成员。自2019年2024年起，本顿女士担任Thea Pharma Inc.的总裁，该公司是一家专门从事眼部护理产品商业化的公司。Benson女士还于2015年至2019年担任Shire plc的全球产品战略和眼科新产品主管，该公司于2019年被Takeda Pharmaceutical Company Limited（NYSE：TAK）收购。在加入Shire之前，2011年至2013年，Benton女士在眼健康公司Bausch + Lomb Corporation（纽约证券交易所代码：BLCO）担任全球业务发展执行董事。Benton co女士创立了Sirion Therapeutics，Inc.并担任其首席商务官，该公司是一家生物制药公司，开发了Durezol（一种用于NIU的类固醇）和Zirgan，后来分别于2010年被爱尔康和Bausch + Lomb收购。此外，Benton女士还在临床开发、战略营销以及商业和商业运营领域担任众多眼科初创公司的战略顾问。本顿女士拥有南弗洛里亚大学MBA学位和穆伦贝格学院生物学学士学位。
- Susan Benton serves as a member of Tarsier Pharma Ltd.'s board of directors, a position she has held since March 2019. Ms. Benton also currently serves on the board of Opus Genetics, Inc. (Nasdaq: IRD), a company focused on developing and advancing treatments to address mutations in genes that cause loss of vision, a position she has held since 2020. Previously, from 2022 2024, Ms. Benson served as a member of the board of directors of Ripple Therapeutics, an ophthalmic clinical stage biotech company. From 2019 2024, Ms. Benton was the President of Thea Pharma Inc., a company specializing in the commercialization of eye care products. Ms. Benson also served as the Head of Global Product Strategy and New and New Ophthalmic Products at Shire plc from 2015 2019, a company that was acquired by Takeda Pharmaceutical Company Limited (NYSE: TAK) in 2019. Prior to joining Shire, from 2011 2013, Ms. Benton served as the Executive Director, Global Business Development at Bausch + Lomb Corporation (NYSE: BLCO), an eye health company. Ms. Benton co founded and served as the Chief Commercial Officer for Sirion Therapeutics, Inc., a biopharmaceutical company that developed Durezol (a steroid for NIU) and Zirgan that were later acquired in 2010 by Alcon and Bausch + Lomb, respectively. Additionally, Ms. Benton has served as a strategic consultant for numerous ophthalmic start up companies in the areas of clinical development, strategic marketing, and commercial and business operations. Ms. Benton holds an MBA from the University of South Floria and a B.S. in Biology from Muhlenberg College.
- Daphne Haim Langford
-
Daphne Haim Langford担任首席执行官，自Tarsier Pharma Ltd.成立以来一直担任该职位，并担任董事会主席，自2020年6月以来一直担任该职位。作为公司创始人，Haim Langford博士带来了超过20年的生物医药创新、风险开发和眼科药物研发经验。迄今为止，Haim Langford博士领导了Tarsier Pharma Ltd.在眼科免疫调节（dazdotuftide平台）方面的企业战略、筹资和临床开发项目。在创立公司之前，2011年至2018年，Haim Langford博士担任Xenia Venture Capital（TASE：XENA）的业务发展副总裁，该公司是一家投资公司，从事以色列高科技、医疗技术和生物技术公司的早期投资，也是耶路撒冷VLX Ventures（孵化器）的运营商，她在那里指导生命科学投资实践，带头进行战略投资，并积极担任领先的医疗技术和生物技术投资组合公司的董事会成员。在加入XENA之前，Haim Langford博士是Medingo Ltd.的业务发展副总裁，在那里她领导了Medingo胰岛素泵技术的开发，该技术后来被收购。Haim Langford博士获得以色列耶路撒冷希伯来大学理学学士学位和以色列理工学院Technion博士学位。
Daphne Haim Langford serves as the Chief Executive Officer, a position she has held since Tarsier Pharma Ltd.'s inception, and Chairperson of the Board, a position she has held since June 2020. To date, Dr. Haim Langford has led Tarsier Pharma Ltd.'s corporate strategy, fundraising, and clinical development programs in ophthalmic immunomodulation (dazdotuftide platform). Prior to founding the Company, from 2011 to 2018, Dr. Haim Langford was the Vice President of Business Development at Xenia Venture Capital (TASE: XENA), an investment company engaged in early stage investments in high tech, med tech and biotech companies in Israel and the operator of VLX ventures (incubator) in Jerusalem, where she directed the life sciences investment practice, spearheading strategic investments and actively serving as a board member of leading medtech and biotech portfolio companies. Prior to joining XENA, Dr. Haim Langford was the Vice President of Business Development at Medingo Ltd., where she provided leadership for the development of Medingo's insulin pump technologies which was later acquired. Dr. Haim Langford received a Bachelor of Science degree from The Hebrew University of Jerusalem Israel and a doctorate from the Technion, Israel Institute of Technology. - Daphne Haim Langford担任首席执行官，自Tarsier Pharma Ltd.成立以来一直担任该职位，并担任董事会主席，自2020年6月以来一直担任该职位。作为公司创始人，Haim Langford博士带来了超过20年的生物医药创新、风险开发和眼科药物研发经验。迄今为止，Haim Langford博士领导了Tarsier Pharma Ltd.在眼科免疫调节（dazdotuftide平台）方面的企业战略、筹资和临床开发项目。在创立公司之前，2011年至2018年，Haim Langford博士担任Xenia Venture Capital（TASE：XENA）的业务发展副总裁，该公司是一家投资公司，从事以色列高科技、医疗技术和生物技术公司的早期投资，也是耶路撒冷VLX Ventures（孵化器）的运营商，她在那里指导生命科学投资实践，带头进行战略投资，并积极担任领先的医疗技术和生物技术投资组合公司的董事会成员。在加入XENA之前，Haim Langford博士是Medingo Ltd.的业务发展副总裁，在那里她领导了Medingo胰岛素泵技术的开发，该技术后来被收购。Haim Langford博士获得以色列耶路撒冷希伯来大学理学学士学位和以色列理工学院Technion博士学位。
- Daphne Haim Langford serves as the Chief Executive Officer, a position she has held since Tarsier Pharma Ltd.'s inception, and Chairperson of the Board, a position she has held since June 2020. To date, Dr. Haim Langford has led Tarsier Pharma Ltd.'s corporate strategy, fundraising, and clinical development programs in ophthalmic immunomodulation (dazdotuftide platform). Prior to founding the Company, from 2011 to 2018, Dr. Haim Langford was the Vice President of Business Development at Xenia Venture Capital (TASE: XENA), an investment company engaged in early stage investments in high tech, med tech and biotech companies in Israel and the operator of VLX ventures (incubator) in Jerusalem, where she directed the life sciences investment practice, spearheading strategic investments and actively serving as a board member of leading medtech and biotech portfolio companies. Prior to joining XENA, Dr. Haim Langford was the Vice President of Business Development at Medingo Ltd., where she provided leadership for the development of Medingo's insulin pump technologies which was later acquired. Dr. Haim Langford received a Bachelor of Science degree from The Hebrew University of Jerusalem Israel and a doctorate from the Technion, Israel Institute of Technology.
- Sascha Bucher
-
Sascha Bucher担任Tarsier Pharma Ltd.董事会成员，自2018年起担任该职位。Bucher先生还是欧洲生物技术风险投资基金Forty51 Ventures的联合创始人和合伙人，他自2021年7月以来一直担任该职位。在此之前，从2017年到2021年，Bucher先生担任Roivant Sciences Ltd.（纳斯达克：ROIV）的合伙人兼董事总经理Investments，该公司是一家生物制药公司，旨在通过加速药物的开发和商业化来改善患者的生活。在加入Roivant之前，Bucher先生曾在业务和企业发展方面担任职务，包括从2009年至2016年在全球制药和诊断公司Roche Holding AG（OTC：RHHBY）担任全球并购副主管。在加入罗氏之前，布彻先生从1992年至1997年在瑞银担任银行家。Bucher先生拥有巴塞尔大学财经MBA学位，是哈佛商学院GMP校友和欧洲注册金融分析师和资产管理公司（CEFA）。
Sascha Bucher serves as a member of Tarsier Pharma Ltd.'s board of directors, a position he has held since 2018. Mr. Bucher is also a Co Founder and Partner at Forty51 ventures, a Biotech VC fund in Europe, a position he has held since July 2021. Previously, from 2017 2021, Mr. Bucher was Partner and Managing Director Investments at Roivant Sciences Ltd. (Nasdaq: ROIV), a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines. Prior to Roivant, Mr. Bucher served in roles in Business and Corporate Development including a role as Deputy Head of Global M&A from 2009 2016 at Roche Holding AG (OTC: RHHBY), a global pharma and diagnostics company. Prior to Roche, Mr. Bucher served as a banker at UBS from 1992 1997. Mr. Bucher holds an MBA in Finance and Economics from the University of Basel, and is a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager (CEFA). - Sascha Bucher担任Tarsier Pharma Ltd.董事会成员，自2018年起担任该职位。Bucher先生还是欧洲生物技术风险投资基金Forty51 Ventures的联合创始人和合伙人，他自2021年7月以来一直担任该职位。在此之前，从2017年到2021年，Bucher先生担任Roivant Sciences Ltd.（纳斯达克：ROIV）的合伙人兼董事总经理Investments，该公司是一家生物制药公司，旨在通过加速药物的开发和商业化来改善患者的生活。在加入Roivant之前，Bucher先生曾在业务和企业发展方面担任职务，包括从2009年至2016年在全球制药和诊断公司Roche Holding AG（OTC：RHHBY）担任全球并购副主管。在加入罗氏之前，布彻先生从1992年至1997年在瑞银担任银行家。Bucher先生拥有巴塞尔大学财经MBA学位，是哈佛商学院GMP校友和欧洲注册金融分析师和资产管理公司（CEFA）。
- Sascha Bucher serves as a member of Tarsier Pharma Ltd.'s board of directors, a position he has held since 2018. Mr. Bucher is also a Co Founder and Partner at Forty51 ventures, a Biotech VC fund in Europe, a position he has held since July 2021. Previously, from 2017 2021, Mr. Bucher was Partner and Managing Director Investments at Roivant Sciences Ltd. (Nasdaq: ROIV), a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines. Prior to Roivant, Mr. Bucher served in roles in Business and Corporate Development including a role as Deputy Head of Global M&A from 2009 2016 at Roche Holding AG (OTC: RHHBY), a global pharma and diagnostics company. Prior to Roche, Mr. Bucher served as a banker at UBS from 1992 1997. Mr. Bucher holds an MBA in Finance and Economics from the University of Basel, and is a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager (CEFA).
高管简历
中英对照 | 中文 | 英文- Arie Ganot
Arie Ganot根据与Ganot先生（“Natig”）拥有的专业咨询公司Natig于2026年1月1日签订的服务协议（“CFO协议”），Ganot先生代表Natig应根据公司不时要求向公司提供外包的财务、会计和执行财务服务，包括但不限于首席财务官服务、会计监督、簿记、财务报告和上市公司财务合规支持（统称“服务”）。Ganot先生在提供服务时将担任公司的首席财务官，并将以兼职为基础，并且Ganot先生将每月至少花费十（10）个小时作为首席财务官的身份提供此处所述的服务。考虑到将履行的服务，公司将向Ganot先生支付75,000美元，以完成此次发行。此外，在此次发行完成后，公司将以首席财务官的身份按小时向Ganot先生支付薪酬，并将就其他服务每月向Natig支付5,000新谢克尔，就任何季度报告支付12,000新谢克尔，就任何年度报告支付30,000新谢克尔。此外，Ganot先生应有权根据其组织文件和适用法律获得给予公司类似情况的高级管理人员的相同赔偿、预支费用和其他保护。CFO协议可由公司或Natig在提前九十（90）天通知后终止。该协议受以色列国法律管辖，受特拉维夫法院专属管辖。
Arie Ganot Based on the services agreement ("CFO Agreement") with Natig, a professional consulting firm owned by Mr. Ganot ("Natig") on January 1, 2026, Mr. Ganot on behalf of Natig shall provide outsourced financial, accounting, and executive financial services to the Company as requested by the Company from time to time, including, without limitation, chief financial officer services, accounting oversight, bookkeeping, financial reporting, and public company financial compliance support (collectively, the "Services"). Mr. Ganot's role in conducting the services will be as Chief Financial Officer of the Company and will be on a part time basis, and Mr. Ganot will spend a minimum of ten (10) hours per month in such capacity as Chief Financial Officer providing the Services as described herein. In consideration of the Services to be performed, the Company will pay Mr. Ganot $75,000 in connection with the consummation of the offering. Additionally, upon the consummation of the offering, the Company will pay Mr. Ganot on an hourly basis in his capacity as Chief Financial Officer and will pay Natig NIS 5,000 per month for other Services, NIS 12,000 for any quarterly reports and NIS 30,000 for any annual reports. Additionally, Mr. Ganot shall be entitled to the same indemnification, advancement of expenses, and other protections afforded to similarly situated officers of the Company under its organizational documents and applicable law. The CFO Agreement may be terminated by either the Company or Natig upon ninety (90) days' notice. The agreement is governed by the laws of the State of Israel and is subject to the exclusive jurisdiction of the courts of Tel Aviv.- Arie Ganot根据与Ganot先生（“Natig”）拥有的专业咨询公司Natig于2026年1月1日签订的服务协议（“CFO协议”），Ganot先生代表Natig应根据公司不时要求向公司提供外包的财务、会计和执行财务服务，包括但不限于首席财务官服务、会计监督、簿记、财务报告和上市公司财务合规支持（统称“服务”）。Ganot先生在提供服务时将担任公司的首席财务官，并将以兼职为基础，并且Ganot先生将每月至少花费十（10）个小时作为首席财务官的身份提供此处所述的服务。考虑到将履行的服务，公司将向Ganot先生支付75,000美元，以完成此次发行。此外，在此次发行完成后，公司将以首席财务官的身份按小时向Ganot先生支付薪酬，并将就其他服务每月向Natig支付5,000新谢克尔，就任何季度报告支付12,000新谢克尔，就任何年度报告支付30,000新谢克尔。此外，Ganot先生应有权根据其组织文件和适用法律获得给予公司类似情况的高级管理人员的相同赔偿、预支费用和其他保护。CFO协议可由公司或Natig在提前九十（90）天通知后终止。该协议受以色列国法律管辖，受特拉维夫法院专属管辖。
- Arie Ganot Based on the services agreement ("CFO Agreement") with Natig, a professional consulting firm owned by Mr. Ganot ("Natig") on January 1, 2026, Mr. Ganot on behalf of Natig shall provide outsourced financial, accounting, and executive financial services to the Company as requested by the Company from time to time, including, without limitation, chief financial officer services, accounting oversight, bookkeeping, financial reporting, and public company financial compliance support (collectively, the "Services"). Mr. Ganot's role in conducting the services will be as Chief Financial Officer of the Company and will be on a part time basis, and Mr. Ganot will spend a minimum of ten (10) hours per month in such capacity as Chief Financial Officer providing the Services as described herein. In consideration of the Services to be performed, the Company will pay Mr. Ganot $75,000 in connection with the consummation of the offering. Additionally, upon the consummation of the offering, the Company will pay Mr. Ganot on an hourly basis in his capacity as Chief Financial Officer and will pay Natig NIS 5,000 per month for other Services, NIS 12,000 for any quarterly reports and NIS 30,000 for any annual reports. Additionally, Mr. Ganot shall be entitled to the same indemnification, advancement of expenses, and other protections afforded to similarly situated officers of the Company under its organizational documents and applicable law. The CFO Agreement may be terminated by either the Company or Natig upon ninety (90) days' notice. The agreement is governed by the laws of the State of Israel and is subject to the exclusive jurisdiction of the courts of Tel Aviv.
- Daphne Haim Langford
Daphne Haim Langford担任首席执行官，自Tarsier Pharma Ltd.成立以来一直担任该职位，并担任董事会主席，自2020年6月以来一直担任该职位。作为公司创始人，Haim Langford博士带来了超过20年的生物医药创新、风险开发和眼科药物研发经验。迄今为止，Haim Langford博士领导了Tarsier Pharma Ltd.在眼科免疫调节（dazdotuftide平台）方面的企业战略、筹资和临床开发项目。在创立公司之前，2011年至2018年，Haim Langford博士担任Xenia Venture Capital（TASE：XENA）的业务发展副总裁，该公司是一家投资公司，从事以色列高科技、医疗技术和生物技术公司的早期投资，也是耶路撒冷VLX Ventures（孵化器）的运营商，她在那里指导生命科学投资实践，带头进行战略投资，并积极担任领先的医疗技术和生物技术投资组合公司的董事会成员。在加入XENA之前，Haim Langford博士是Medingo Ltd.的业务发展副总裁，在那里她领导了Medingo胰岛素泵技术的开发，该技术后来被收购。Haim Langford博士获得以色列耶路撒冷希伯来大学理学学士学位和以色列理工学院Technion博士学位。
Daphne Haim Langford serves as the Chief Executive Officer, a position she has held since Tarsier Pharma Ltd.'s inception, and Chairperson of the Board, a position she has held since June 2020. To date, Dr. Haim Langford has led Tarsier Pharma Ltd.'s corporate strategy, fundraising, and clinical development programs in ophthalmic immunomodulation (dazdotuftide platform). Prior to founding the Company, from 2011 to 2018, Dr. Haim Langford was the Vice President of Business Development at Xenia Venture Capital (TASE: XENA), an investment company engaged in early stage investments in high tech, med tech and biotech companies in Israel and the operator of VLX ventures (incubator) in Jerusalem, where she directed the life sciences investment practice, spearheading strategic investments and actively serving as a board member of leading medtech and biotech portfolio companies. Prior to joining XENA, Dr. Haim Langford was the Vice President of Business Development at Medingo Ltd., where she provided leadership for the development of Medingo's insulin pump technologies which was later acquired. Dr. Haim Langford received a Bachelor of Science degree from The Hebrew University of Jerusalem Israel and a doctorate from the Technion, Israel Institute of Technology.- Daphne Haim Langford担任首席执行官，自Tarsier Pharma Ltd.成立以来一直担任该职位，并担任董事会主席，自2020年6月以来一直担任该职位。作为公司创始人，Haim Langford博士带来了超过20年的生物医药创新、风险开发和眼科药物研发经验。迄今为止，Haim Langford博士领导了Tarsier Pharma Ltd.在眼科免疫调节（dazdotuftide平台）方面的企业战略、筹资和临床开发项目。在创立公司之前，2011年至2018年，Haim Langford博士担任Xenia Venture Capital（TASE：XENA）的业务发展副总裁，该公司是一家投资公司，从事以色列高科技、医疗技术和生物技术公司的早期投资，也是耶路撒冷VLX Ventures（孵化器）的运营商，她在那里指导生命科学投资实践，带头进行战略投资，并积极担任领先的医疗技术和生物技术投资组合公司的董事会成员。在加入XENA之前，Haim Langford博士是Medingo Ltd.的业务发展副总裁，在那里她领导了Medingo胰岛素泵技术的开发，该技术后来被收购。Haim Langford博士获得以色列耶路撒冷希伯来大学理学学士学位和以色列理工学院Technion博士学位。
- Daphne Haim Langford serves as the Chief Executive Officer, a position she has held since Tarsier Pharma Ltd.'s inception, and Chairperson of the Board, a position she has held since June 2020. To date, Dr. Haim Langford has led Tarsier Pharma Ltd.'s corporate strategy, fundraising, and clinical development programs in ophthalmic immunomodulation (dazdotuftide platform). Prior to founding the Company, from 2011 to 2018, Dr. Haim Langford was the Vice President of Business Development at Xenia Venture Capital (TASE: XENA), an investment company engaged in early stage investments in high tech, med tech and biotech companies in Israel and the operator of VLX ventures (incubator) in Jerusalem, where she directed the life sciences investment practice, spearheading strategic investments and actively serving as a board member of leading medtech and biotech portfolio companies. Prior to joining XENA, Dr. Haim Langford was the Vice President of Business Development at Medingo Ltd., where she provided leadership for the development of Medingo's insulin pump technologies which was later acquired. Dr. Haim Langford received a Bachelor of Science degree from The Hebrew University of Jerusalem Israel and a doctorate from the Technion, Israel Institute of Technology.
- Zohar Milman
Zohar Milman担任Tarsier Pharma Ltd.的首席运营官，自2017年3月起担任该职位。从2014年至2016年，Milman女士在VLX Ventures担任业务发展经理，这是一家风险投资公司，她在那里管理早期项目的尽职调查流程，并为医疗器械和制药领域的投资组合公司提供支持。在加入VLX Ventures之前，从2012年到2014年，Milman女士在Neopharm Life Science Ventures担任研究助理，该公司专注于开发治疗罕见、威胁生命的疾病的新药，该公司被Retrophin Inc.（现称为Travere Therapeutics, Inc.）（纳斯达克：TVTX）收购。Milman女士拥有以色列耶路撒冷希伯来大学生物医学科学和人类遗传学硕士学位。
Zohar Milman serves as Tarsier Pharma Ltd.'s Chief Operating Officer, a position she has held since March 2017. From 2014 2016, Ms. Milman served as Business Development Manager at VLX Ventures, a venture capital firm where she managed due diligence processes for early stage projects, and supported portfolio companies in the medical device and pharmaceutical sectors. Prior to VLX Ventures, from 2012 2014, Ms. Milman served as a Research Associate at Neopharm Life Science Ventures, a company focused on development of novel drugs for rare, life threatening diseases that was acquired by Retrophin Inc., now known as Travere Therapeutics, Inc. (Nasdaq: TVTX). Ms. Milman holds an M.Sc. in Biomedical Sciences and Human Genetics from the Hebrew University of Jerusalem, Israel.- Zohar Milman担任Tarsier Pharma Ltd.的首席运营官，自2017年3月起担任该职位。从2014年至2016年，Milman女士在VLX Ventures担任业务发展经理，这是一家风险投资公司，她在那里管理早期项目的尽职调查流程，并为医疗器械和制药领域的投资组合公司提供支持。在加入VLX Ventures之前，从2012年到2014年，Milman女士在Neopharm Life Science Ventures担任研究助理，该公司专注于开发治疗罕见、威胁生命的疾病的新药，该公司被Retrophin Inc.（现称为Travere Therapeutics, Inc.）（纳斯达克：TVTX）收购。Milman女士拥有以色列耶路撒冷希伯来大学生物医学科学和人类遗传学硕士学位。
- Zohar Milman serves as Tarsier Pharma Ltd.'s Chief Operating Officer, a position she has held since March 2017. From 2014 2016, Ms. Milman served as Business Development Manager at VLX Ventures, a venture capital firm where she managed due diligence processes for early stage projects, and supported portfolio companies in the medical device and pharmaceutical sectors. Prior to VLX Ventures, from 2012 2014, Ms. Milman served as a Research Associate at Neopharm Life Science Ventures, a company focused on development of novel drugs for rare, life threatening diseases that was acquired by Retrophin Inc., now known as Travere Therapeutics, Inc. (Nasdaq: TVTX). Ms. Milman holds an M.Sc. in Biomedical Sciences and Human Genetics from the Hebrew University of Jerusalem, Israel.
- Ron Neumann
Ron Neumann担任Tarsier Pharma Ltd.的首席医疗官（约50%的时间为公司工作），他自2017年4月以来一直担任该职位。Neumann博士是一名眼科医生，专门研究眼部免疫学和葡萄膜炎。自2018年起，Neumann博士担任宝莱特生命科学有限公司（TASE：BOLT.TA）的首席医疗官，该公司投资于从事眼科领域先进医疗器械的公司。Neumann博士目前还担任眼科制药公司Orasis Pharmaceuticals的首席医疗官，他自2016年以来一直担任该职位。此前，从2002年到2016年，Neumann博士在制药公司梯瓦制药有限公司（纽约证券交易所代码：TEVA）担任治疗领域负责人，负责全球临床开发。在加入Teva之前，从1997年到2002年，Neumann博士是Maccabi Healthcare Services的临床研究医学主任。从1992年到1998年，Neumann博士担任Pharmos公司的眼科研究主管，该公司是一家支持临床和辅助医疗项目的公司。自1995年以来，Neumann博士一直担任国际眼药理学和治疗学（ISOPT）临床研讨会的创始人和联合主席。Neumann博士在以色列特拉维夫大学萨克勒医学院获得医学博士学位，并在哈佛大学大众眼耳医院完成了眼部免疫学研究金。
Ron Neumann serves as Tarsier Pharma Ltd.'s Chief Medical Officer (spending approximately 50% of his time working for the Company), a position he has held since April 2017. Dr. Neumann is an ophthalmologist, specializing in ocular immunology and uveitis. Since 2018, Dr. Neumann has served as the Chief Medical Officer of Biolight Life Sciences Ltd. (TASE: BOLT.TA), which invests in companies engaging in advanced medical devices in the Ophthalmology space. Dr. Neumann also currently serves as the Chief Medical Officer of Orasis Pharmaceuticals, an ophthalmic pharmaceutical company, a position he has held since 2016. Previously, from 2002 2016, Dr. Neumann served as the Therapeutic Area Head, Global Clinical Development at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a pharmaceutical company. Prior to Teva, from 1997 2002, Dr. Neumann was the Medical Director of Clinical Research at Maccabi Healthcare Services. From 1992 1998, Dr. Neumann served as the Head of Ophthalmic Research for Pharmos Corporation, a company that supports clinical and paramedical projects. Since 1995, Dr. Neumann has served as the Founder and Co Chairman of the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) Clinical. Dr. Neumann received his M.D. from Sackler Medical School, Tel Aviv University, Israel and completed a fellowship in Ocular Immunology at Mass Eye and Ear Infirmary, Harvard University.- Ron Neumann担任Tarsier Pharma Ltd.的首席医疗官（约50%的时间为公司工作），他自2017年4月以来一直担任该职位。Neumann博士是一名眼科医生，专门研究眼部免疫学和葡萄膜炎。自2018年起，Neumann博士担任宝莱特生命科学有限公司（TASE：BOLT.TA）的首席医疗官，该公司投资于从事眼科领域先进医疗器械的公司。Neumann博士目前还担任眼科制药公司Orasis Pharmaceuticals的首席医疗官，他自2016年以来一直担任该职位。此前，从2002年到2016年，Neumann博士在制药公司梯瓦制药有限公司（纽约证券交易所代码：TEVA）担任治疗领域负责人，负责全球临床开发。在加入Teva之前，从1997年到2002年，Neumann博士是Maccabi Healthcare Services的临床研究医学主任。从1992年到1998年，Neumann博士担任Pharmos公司的眼科研究主管，该公司是一家支持临床和辅助医疗项目的公司。自1995年以来，Neumann博士一直担任国际眼药理学和治疗学（ISOPT）临床研讨会的创始人和联合主席。Neumann博士在以色列特拉维夫大学萨克勒医学院获得医学博士学位，并在哈佛大学大众眼耳医院完成了眼部免疫学研究金。
- Ron Neumann serves as Tarsier Pharma Ltd.'s Chief Medical Officer (spending approximately 50% of his time working for the Company), a position he has held since April 2017. Dr. Neumann is an ophthalmologist, specializing in ocular immunology and uveitis. Since 2018, Dr. Neumann has served as the Chief Medical Officer of Biolight Life Sciences Ltd. (TASE: BOLT.TA), which invests in companies engaging in advanced medical devices in the Ophthalmology space. Dr. Neumann also currently serves as the Chief Medical Officer of Orasis Pharmaceuticals, an ophthalmic pharmaceutical company, a position he has held since 2016. Previously, from 2002 2016, Dr. Neumann served as the Therapeutic Area Head, Global Clinical Development at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a pharmaceutical company. Prior to Teva, from 1997 2002, Dr. Neumann was the Medical Director of Clinical Research at Maccabi Healthcare Services. From 1992 1998, Dr. Neumann served as the Head of Ophthalmic Research for Pharmos Corporation, a company that supports clinical and paramedical projects. Since 1995, Dr. Neumann has served as the Founder and Co Chairman of the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) Clinical. Dr. Neumann received his M.D. from Sackler Medical School, Tel Aviv University, Israel and completed a fellowship in Ocular Immunology at Mass Eye and Ear Infirmary, Harvard University.